Back to search
Metastatic Sporadic Medullary Thyroid Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Metastatic Sporadic Medullary Thyroid Cancer trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Metastatic Sporadic Medullary Thyroid Cancer trials you may qualify forThe purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD64…
This is a European multinational, multicenter, non-interventional (observational) and prospective study. It is carried on to confirm in real life conditions the…
This phase II trial studies how well sorafenib tosylate works in treating patients with medullary thyroid cancer that has spread to other parts of the body (met…
The oncologic benefit of lateral neck dissection (LND) during index operation for sporadic medullary thyroid carcinoma (MTC) basing on basal calcitonin (bCT) le…
Vandetanib has been approved for patients with unresectable and/or metastatic medullary thyroid cancer (MTC) by the Food and Drug Administration, by the Europea…
Background: * The combination of anti-cancer drugs vandetanib (given orally) and bortezomib (given intravenously) has not been used in humans. However, both dr…